Literature DB >> 7585219

A picornaviral protein synthesized out of frame with the polyprotein plays a key role in a virus-induced immune-mediated demyelinating disease.

H H Chen1, W P Kong, L Zhang, P L Ward, R P Roos.   

Abstract

The DA strain and other members of the TO subgroup of Theiler's murine encephalomyelitis virus (TMEV) induce a chronic demyelinating disease with a restricted virus expression. This disease serves as an experimental model of multiple sclerosis; in both diseases the immune system contributes to a similar demyelinating pathology. Like all picornaviruses, TMEV encodes a polyprotein translated from one long open reading frame. The polyprotein is then processed into structural and non-structural viral proteins. Here, we demonstrate that the DA strain of TMEV has an additional alternative open reading frame that encodes a protein called L* that is present in infected cells. Virus with a mutation of L* has a dramatically decreased demyelinating activity, indicating that L* plays a critical role in TO subgroup-induced demyelinating disease. L* is associated with membranes, suggesting that L* may interact with the immune system and thereby mediate the viral-induced demyelinating disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585219     DOI: 10.1038/nm0995-927

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  29 in total

1.  L* protein of Theiler's murine encephalomyelitis virus is required for virus growth in a murine macrophage-like cell line.

Authors:  M Obuchi; J Yamamoto; T Odagiri; M N Uddin; H Iizuka; Y Ohara
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  The leader polypeptide of Theiler's murine encephalomyelitis virus is required for the assembly of virions in mouse L cells.

Authors:  C Badshah; M A Calenoff; K Rundell
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Prevalent class I-restricted T-cell response to the Theiler's virus epitope Db:VP2121-130 in the absence of endogenous CD4 help, tumor necrosis factor alpha, gamma interferon, perforin, or costimulation through CD28.

Authors:  A J Johnson; M K Njenga; M J Hansen; S T Kuhns; L Chen; M Rodriguez; L R Pease
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 4.  Viral internal ribosome entry site elements: novel ribosome-RNA complexes and roles in viral pathogenesis.

Authors:  Peter Sarnow
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

5.  Epitope-tagged L* protein of Theiler's murine encephalomyelitis virus is expressed in the central nervous system in the acute phase of infection.

Authors:  Kunihiko Asakura; Harunobu Murayama; Toshiki Himeda; Yoshiro Ohara
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

6.  Different strains of Theiler's murine encephalomyelitis virus antagonize different sites in the type I interferon pathway.

Authors:  Spyridon Stavrou; Zongdi Feng; Stanley M Lemon; Raymond P Roos
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

7.  The L-coding region of the DA strain of Theiler's murine encephalomyelitis virus causes dysfunction and death of myelin-synthesizing cells.

Authors:  G D Ghadge; R Wollmann; G Baida; M Traka; R P Roos
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

8.  Different subcellular localization of Theiler's murine encephalomyelitis virus leader proteins of GDVII and DA strains in BHK-21 cells.

Authors:  Naoko Taniura; Mineki Saito; Takako Okuwa; Kousuke Saito; Yoshiro Ohara
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

9.  A subgenomic segment of Theiler's murine encephalomyelitis virus RNA causes demyelination.

Authors:  Gleb Baida; Brian Popko; Robert L Wollmann; Spyridon Stavrou; Wensheng Lin; Maria Tretiakova; Thomas N Krausz; Raymond P Roos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

10.  Phylogenetic analysis of the species Theilovirus: emerging murine and human pathogens.

Authors:  Zhiguo Liang; A S Manoj Kumar; Morris S Jones; Nick J Knowles; Howard L Lipton
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.